GLP-1 Lawsuit & News Tracker: Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity

A large study found that people taking GLP-1 drugs were more likely to be diagnosed with hair loss than patients using two other common classes of diabetes medication.

An insurance denial does not always mean the case is closed. Patients seeking coverage for Wegovy, Zepbound or another GLP-1 medication may have several opportunities to challenge the decision.

The drugs may deliver good value for each patient, but covering everyone who qualifies could overwhelm health-plan budgets.

The goal is to solve one of the biggest problems with GLP-1 drugs: patients quitting treatment because of cost, side effects or injection fatigue.

Attorneys on both sides of MDL 3094 and MDL 3163 are maneuvering and jockeying for position as multi-district litigation against the makers of GLP-1 drugs including Ozempic, Wegovy, Rybelsus, Trulicity and Mounjaro edges closer to actual testimony. The cases break down into two categories: those claiming gastrointestinal injury

The GLP-1 “bridge” is confusing to get into and its benefits are questionable given its temporary nature.

A new pilot Medicare program, “set to continue through 2027, will allow older adults to access GLP-1 medications for $50 per month” — the first time the program will cover them specifically for weight loss,

Regulators say some firms falsely implied their products were equivalent to FDA-approved medications such as Wegovy, Ozempic, Zepbound, and Mounjaro. The U.S. Food and Drug Administration has intensified its campaign against the booming online weight-loss drug industry, issuing warning letters to 25 telehealth companies that allegedly made

Powerful new GLP-1 weight‑loss drugs promise longer, healthier lives for millions of people — but they are also reshaping everything from insurance premiums to clothing racks, while raising fresh questions about safety, cost and who gets access to the “Ozempic revolution.”

The cases involve Ozempic, Wegovy, Mounjaro, Zepbound and Trulicity Federal litigation over the blockbuster class of GLP-1 drugs that includes Ozempic, Wegovy, Mounjaro, Zepbound and Trulicity has ballooned to more than 3,600 pending cases across two multidistrict proceedings, as a federal judge moves to tighten the medical evidence

The popular diabetes and weight-loss drugs may also help prevent Alzheimer’s, according to one study

Ozempic, Wagovy, Mounjaro, Zepbound take the field, with ‘compounded’ versions at their heels

Marketers and their publicists are hawking tiny doses of GLP-1 but there’s no evidence it’s effective